・Cybin (Cboe CA:CYBN) has begun its Phase 3 pivotal program, PARADIGM, to evaluate the efficacy and safety of CYB003 as an adjunctive treatment for Major Depressive Disorder (MDD) ・The PARADIGM ...
AMSTERDAM, Sept. 11, 2012 /PRNewswire/ -- Paradigm™ (www.pdgm.com) today announced that it has joined the NetApp Alliance Partner Program, as part of its collaboration with NetApp to offer optimized ...
NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Paradigm Biopharmaceuticals Ltd (ASX: PAR) ("Paradigm" or "the Company"), a late-stage drug development company, is pleased to announce that it is scheduled to ...
TAMPA, Fla., May 07, 2026--(BUSINESS WIRE)--Paradigm, a specialty care management organization focused on delivering value-based solutions to improve outcomes for patients, payers, and providers, ...
- PARADIGM ™ program comprises two 12-week randomized, placebo-controlled studies (APPROACH and EMBRACE) and a long-term extension study (EXTEND) - - EXTEND: a Phase III Open Label Extension Study ...
Paradigm and Film2Future have inked a two-year collaborative agreement that will see the talent agency become the exclusive partner of the non-profit that promotes pathways into the entertainment ...